Actively Recruiting
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2025-12-24
132
Participants Needed
1
Research Sites
617 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
CONDITIONS
Official Title
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of NSCLC Stage IV according to American Joint Committee on Cancers - 7th edition
- Candidates for first-line treatment with carboplatin plus paclitaxel
- Performance status (ECOG) between 0 and 2
- Laboratory tests showing adequate kidney, liver, and blood function
- Normal kidney ultrasound before starting treatment
You will not qualify if you...
- Kidney impairment classified as KDOQI stages 3 to 5
- Lack of baseline computed tomography study
- Uncontrolled blood pressure above 140 mmHg
- Uncontrolled diabetes with blood sugar over 130 mg/dL
- Obstruction in one or both kidneys or ureters
- Dehydration
- High use of NSAIDs (aspirin, ibuprofen, etc.) for more than 1 month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto Nacional de Cancerologia
Mexico City, Mexico, 14080
Actively Recruiting
Research Team
O
Oscar Arrieta, MD, M Sc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here